BioRay Pharmaceutical Co., Ltd.

Quick facts

Marketed products

• Perjeta · Oncology

Phase 3 pipeline

• HS627 · Diabetes
  HS627 is a small molecule that targets the SGLT2 receptor.

Phase 2 pipeline

• BRY812 for injection · Oncology
  BRY812 for injection is a monoclonal antibody that targets the PD-1 receptor.

Phase 1 pipeline

• BR101
• BR201
• Cosentyx（Secukinumab ）

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• BioRay Pharmaceutical Co., Ltd. portfolio CI brief
• BioRay Pharmaceutical Co., Ltd. pipeline updates RSS